genetic medicines
Oligonucleotide Design Studio
AI-Enabled Efficiency
Accelerating Discovery Through Predictive Insight
Alloy Genetic Medicines’ Oligonucleotide Design Studio transforms genetic medicine discovery from a sea of possibilities into a process of predictive precision. By screening hundreds of thousands of potential sequences in silico, our computational experts identify the highest-probability candidates, sharply reducing the resources required for synthesis and wet lab experimentation. We integrate our genomics expertise with machine learning to navigate vast sequence spaces, compressing years of traditional screening into days and facilitating shortened IND filing timelines.
Speed & Expertise
Rational Multi-Parameter Optimization for Efficient Sequence Discovery
By combining genomic context with predictive modeling, we efficiently select high-conviction candidates from the start. Our platform leverages AI for unparalleled efficiency while remaining grounded in human expertise. Our multidimensional workflow identifies the most effective sequences, balancing computational speed with the expertise required for clinical success.
- Target Review
We assess sequences across multidimensions, integrating genomic location and isoforms with biochemical and biophysical properties. This multi-parameter review optimizes structural and sequence stability while mitigating off-target risks, ensuring every candidate is safe, potent, and development-ready.
- Bioinformatics & ML-Based Scoring
Our Oligonucleotide Design Studio utilizes machine learning (ML) and KMER scores to decode complex patterns and structural motifs. Integrated with Reference ML Scores, these metrics benchmark designs against global datasets, distilling hundreds of thousands of possibilities into a set of priority candidates.
- Filter & Rank
AntiClastic sgRNAs leverage a proprietary cyclic architecture to stabilize the guide RNA structure, thereby enhancing CRISPR-Cas9 precision. By shielding reactive ends, the platform increases nuclease resistance and significantly reduces off-target activity. This structural engineering optimizes on-target cleavage while minimizing immunogenicity, providing a safer, more potent engine for advanced genome editing.
- Evaluate Project-Specific Features
We perform additional bespoke studies, including conservation and splicing analyses, to ensure target precision across populations. By integrating cancer-specific and patient-level genomic data, we refine candidates for specific disease drivers, delivering personalized assets tailored to complex, real-world clinical needs.
- Final Selection of Candidates
AI-prioritized sequences undergo rigorous review by our molecular experts. Our human-in-the-loop approach ensures that every candidate meets developability standards, fusing computational velocity with scientific intuition to identify the most efficacious leads before wet lab validation begins.
Reduce Time & Cost
Streamlining RNA Therapeutic Discovery
The Oligonucleotide Design Studio provides a strategic advantage by digitally front-loading the discovery process. We eliminate low-probability experimentation, quickly deliver high-conviction leads, and enable ongoing learning and data collection that further enhance capabilities over time.
Rapid Turnaround
Our Oligonucleotide Design Studio team moves from target identification to prioritized candidate selection in days rather than months. This compression accelerates discovery, providing an industry-leading 18-month line of sight from initial synthesis to IND.
Maximal Information, Minimal Experiments
Our Oligonucleotide Design Studio team moves from target identification to prioritized candidate selection in days rather than months. This compression accelerates discovery, providing an industry-leading 18-month line of sight from initial synthesis to IND.Identifying high-probability candidates in silico reduces R&D costs and focuses resources on candidates with the highest potential efficacy.
Continuous Feedback Loop
Our continuous learning loop integrates insights from ongoing data mining and wet lab data from every project, refining our predictive models. By analyzing both hits and misses, we sharpen our accuracy, ensuring future designs are progressively smarter.
Innovation Infrastructure
Unlocking the Potential of RNA Therapeutics with AntiClastic Innovation
Resources
Join Us in Shaping the RNA Century
Whether you are a global pharma leader, biotech, academic team, or other industry stakeholder, partner with Alloy Genetic Medicines to deliver next-generation genetic medicines to patients who need them.
